УДК 61 Медицина. Охрана здоровья
Микофенолата мофетил представляет собой антиметаболит с мощным ингибирующим действием на пролиферацию Т- и В-лимфоцитов, препарат используется с начала 1990-х годов для профилактики острого отторжения трансплантата после трансплантации органов. Он также широко используется для лечения различных ревматических заболеваний с поражением легких. Интерстициальное заболевание легких – это гетерогенная группа прогрессирующих фиброзных заболеваний легких, которое часто является вторичным по отношению к ревматическому заболеванию и является частой причиной смертности. Микофенолата мофетил является основной альтернативой циклофосфамиду в качестве препарата первой линии для лечения интерстициальных заболеваний легких, связанных с ревматическими заболеваниями, или в качестве возможной поддерживающей терапии после лечения циклофосфамидом с меньшей частотой побочных эффектов. Однако применение микофенолата мофетила при интерстициальных заболеваниях легких, ассоциированных с ревматическими заболеваниями, имеет недостаточно обширные научные данные. В обзоре описаны современные сведения и достижения в области применения, эффективности и безопасности микофенолата мофетила.
: заболевания соединительной ткани, интерстициальная болезнь легких, ревматические заболевания, ревматоидный артрит, системная красная волчанка, системная склеродермия, микофенолата мофетил, азатиоприн, циклофосфамид.
1. Lipsky JJ. Drug profile mycophenolate mofetil. Lancet. 1996;348:1357–1359. https://doi.org/10.1016/S0140-6736(96)10310-X
2. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2–3):85–118. https://doi.org/10.1016/S0162-3109(00)00188-0
3. Demedts M, Costabel U. American Thoracic Society American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Eur Respir J. 2002;19(5):794–796. https://doi.org/10.1183/09031936.02.00492002
4. Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34(6):429–455. https://doi.org/10.2165/00003088-199834060-00002
5. FDA. CellCept® (Mycophenolate Mofetil Capsules) (Mycophenolate Mofetil Tablets) CellCept® Oral Suspension (Mycophenolate Mofetil for Oral Suspension) CellCept® Intravenous (Mycophenolate Mofetil Hydrochloride for Injection).https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050722s021,050723s019,050758s019,050759s024lbl.pdf. Accessed July 20, 2020.
6. Vernino S, Salomao DR, Habermann TM, O’Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology. 2005;65(4):639–641. tps://doi.org/10.1212/01.wnl.0000173031.56429.04.
7. Budde K, Drr M, Liefeldt L, Neumayer HH, Glander P. Enteric-coated mycophenolate sodium. Expert Opin Drug Saf. 2010;9(6): 981–994. https://doi.org/10.1517/14740338.2010.513379
8. Salvadori M, Bertoni E, Budde K. Superior efficacy of enteric-coated ycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis. TPS. 2010;42:1325–1328. https://doi.org/10.1016/j.transproceed.2010.03.044
9. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–646. https://doi.org/10.3899/jrheum.121043
10. Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med. 2008;168(15):1718–1719. https://doi.org/10.1001/archinte.168.15.1718
11. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009;337(5):329–335. https://doi.org/10.1097/MAJ.0b013e31818d094b
12. Kelly C, Young A, Ahmad Y, et al. The effect of steroids, azathioprine and mycophenolate on the risk of death in rheumatoid arthritis. Rheumatology. 2016;55:i99–i100. https://doi.org/10.1093/rheumatology/kew144.019
13. Oldham JM, Lee C, Valenzi E, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. 2016;121:P117–122. https://doi.org/10.1016/j.rmed.2016.11.007
14. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130(1):30–36.
15. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–646. https://doi.org/10.3899/jrheum.121043
16. Zhang G, Xu T, Zhang H, et al. [Randomized control multi-center clinical study of mycophenolate mofetil and cyclophosphamide in the treatment of connective tissue disease related interstitial lung disease]. Zhonghua Yi Xue Za Zhi. 2015;95(45):3641–3645.
17. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009;337(5):329–335. https://doi.org/10.1097/MAJ.0b013e31818d094b
18. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–646. https://doi.org/10.3899/jrheum.121043
19. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2010;29(10):1167–1168. https://doi.org/10.1007/s10067-010-1498-z
20. Baqir M, Makol A, Osborn TG, Bartholmai BJ, Ryu JH. Mycophenolate mofetil for scleroderma-related interstitial lung disease: a real world experience. PLoS One. 2017;12(5):e0177107. https://doi.org/10.1371/journal.pone.0177107
21. Panopoulos ST, Bournia VK, Trakada G, Giavri I, Kostopoulos C, Sfikakis PP. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung. 2013;191(5):483–489.https://doi.org/10.1007/s00408-013-9499-8
22. Erre GL, Sebastiani M, Fenu MA, et al. Efficacy, safety, and tolerability of treatments for systemic sclerosis-related interstitial lung disease: a systematic review and network meta-analysis. J Clin Med. 2020;9(8):2560. https://doi.org/10.3390/jcm9082560
23. Scleroderma Lung Study III – Combining pirfenidone with mycophenolate – Full Text View – ClinicalTrials.gov.. https://clinicaltrials.gov/ct2/show/NCT03221257. Accessed May 11, 2020
24. Mira-Avendano IC, Parambil JG, Yadav R, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from olymyositis/dermatomyositis. Respir Med. 2013;107(6): 890–896
25. Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy. Clin Rheumatol. 2019;38(2):585–590. https://doi.org/10.1007/s10067-018-4294-9
26. Muangchan C, Van Vollenhoven RF, Bernatsky SR, et al. Treatment lgorithms in systemic lupus erythematosus. Arthritis Care Res. 2015;67(9):1237–1245. https://doi.org/10.1002/acr.22589
27. Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with nclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147–157. https://doi.org/10.1016/S2213-2600(19)30341-8
28. Vacchi C, Sebastiani M, Cassone G, et al. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. a narrative review. J Clin Med. 2020;9(2):407. https://doi.org/10.3390/jcm9020407
29. Cassone G, Manfredi A, Vacchi C, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. J Clin Med. 2020;9(4):1082. https://doi.org/10.3390/jcm9041082
